These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 27879971)

  • 1. TCR diversity - a universal cancer immunotherapy biomarker?
    McNeel DG
    J Immunother Cancer; 2016; 4():69. PubMed ID: 27879971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell receptor repertoire usage in cancer as a surrogate marker for immune responses.
    Schrama D; Ritter C; Becker JC
    Semin Immunopathol; 2017 Apr; 39(3):255-268. PubMed ID: 28074285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D: diversity, dynamics, differential testing - a proposed pipeline for analysis of next-generation sequencing T cell repertoire data.
    Zhang L; Cham J; Paciorek A; Trager J; Sheikh N; Fong L
    BMC Bioinformatics; 2017 Feb; 18(1):129. PubMed ID: 28241742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonotypic Diversification of Intratumoral T Cells Following Sipuleucel-T Treatment in Prostate Cancer Subjects.
    Sheikh N; Cham J; Zhang L; DeVries T; Letarte S; Pufnock J; Hamm D; Trager J; Fong L
    Cancer Res; 2016 Jul; 76(13):3711-8. PubMed ID: 27216195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer-killing CAR therapies gain speed.
    Weber M
    Cancer Discov; 2015 Jan; 5(1):7. PubMed ID: 25583785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
    Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN
    Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naturally Occurring Genetic Alterations in Proximal TCR Signaling and Implications for Cancer Immunotherapy.
    Kent A; Longino NV; Christians A; Davila E
    Front Immunol; 2021; 12():658611. PubMed ID: 34012443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of TCR β CDR3 sequencing data for tracking anti-tumor immunity.
    Zhang J; Ji Z; Smith KN
    Methods Enzymol; 2019; 629():443-464. PubMed ID: 31727253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Helping CAR T cells reach tumors.
    Cancer Discov; 2015 Jan; 5(1):OF6. PubMed ID: 25583818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fine-tuning the effects of T-cell therapy.
    Cancer Discov; 2014 Feb; 4(2):137. PubMed ID: 24501286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
    Wei XX; Fong L; Small EJ
    Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Armed T cells with CAR for cancer immunotherapy.
    Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):331-2. PubMed ID: 27080712
    [No Abstract]   [Full Text] [Related]  

  • 13. NOTCH Signaling in T-Cell-Mediated Anti-Tumor Immunity and T-Cell-Based Immunotherapies.
    Kelliher MA; Roderick JE
    Front Immunol; 2018; 9():1718. PubMed ID: 30967879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TCR repertoires of intratumoral T-cell subsets.
    Linnemann C; Mezzadra R; Schumacher TN
    Immunol Rev; 2014 Jan; 257(1):72-82. PubMed ID: 24329790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies to genetically engineer T cells for cancer immunotherapy.
    Spear TT; Nagato K; Nishimura MI
    Cancer Immunol Immunother; 2016 Jun; 65(6):631-49. PubMed ID: 27138532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell receptor-engineered T cells for cancer treatment: current status and future directions.
    Ping Y; Liu C; Zhang Y
    Protein Cell; 2018 Mar; 9(3):254-266. PubMed ID: 28108950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skewed T-cell receptor repertoire: more than a marker of malignancy, a tool to dissect the immunopathology of inflammatory diseases.
    Pandolfi F; Cianci R; Casciano F; Pagliari D; De Pasquale T; Landolfi R; Di Sante G; Kurnick JT; Ria F
    J Biol Regul Homeost Agents; 2011; 25(2):153-61. PubMed ID: 21880203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
    Di S; Li Z
    Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer.
    Hombach AA; Abken H
    Immunotherapy; 2013 Jul; 5(7):677-81. PubMed ID: 23829616
    [No Abstract]   [Full Text] [Related]  

  • 20. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
    Houot R; Schultz LM; Marabelle A; Kohrt H
    Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.